Pacira nerve block misses primary endpoint in Phase 3 study

 Study did not demonstrate statistical significance for primary endpoint of pain reduction from 0 to 96 hours for EXPAREL versus bupivacaine HCl --

-- EXPAREL achieves highly statistically significant reductions in pain and total opioid consumption from 24 to 96 hours versus bupivacaine HCl (p<0.01) --

-- EXPAREL also hits statistical significance for area under the curve cumulative pain scores from 12 to 96 hours versus bupivacaine HCl (p<0.02) --

https://finance.yahoo.com/news/pacira-biosciences-announces-top-line-120000217.html